Maternal Medications and Human Milk Research Center (M2HMRC)
ID: 360585Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360585
Timeline
    Description

    The National Institutes of Health (NIH) is set to announce a funding opportunity for the establishment of the Maternal Medications and Human Milk Research Center (M2HMRC) as part of its Maternal and Pediatric Precision in Therapeutics (MPRINT) Hub. This initiative aims to advance research on the impact of maternal medications on human milk composition and neonatal health outcomes by addressing knowledge gaps, integrating real-world evidence, developing innovative safety tools, and disseminating findings to a wide audience. The total estimated funding for this cooperative agreement is $2.5 million, with one award anticipated, and applications are expected to be solicited following the publication of the Notice of Funding Opportunity (NOFO) on November 3, 2025. Interested parties can reach out to Dr. Zhaoxia Ren at zren@mail.nih.gov or by phone at 240-463-5046 for further information.

    Point(s) of Contact
    Zhaoxia Ren, M.D., Ph.D.
    (240) 463-5046
    zren@mail.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Maternal and Pediatric Precision in Therapeutics (MPRINT) Knowledge and Research Coordination Center
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the establishment of the Maternal and Pediatric Precision in Therapeutics (MPRINT) Knowledge and Research Coordination Center through a cooperative agreement. This initiative aims to enhance drug development and regulatory science for maternal and pediatric therapeutics by creating a pharmacology knowledgebase, utilizing real-world clinical data, and fostering innovative clinical trials, while also training the future workforce in this critical area. The total estimated funding for this program is $3,625,000, with one award anticipated, and interested parties can reach out to Lesly-Anne Samedy-Bates at lesly-anne.samedy-bates@nih.gov or by phone at 301-219-7492 for further information. The estimated synopsis post date is November 21, 2025, with a closing date for applications expected by March 2, 2026, and project commencement anticipated on December 1, 2026.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing research in drug safety and effectiveness for pregnant individuals, lactating persons, and children. This initiative seeks to support innovative projects that develop novel methodologies, enhance understanding of drug mechanisms, and promote precision medicine to address significant unmet medical needs in maternal and pediatric health. Eligible applicants include a wide range of institutions, such as historically black colleges and universities, tribal colleges, and various nonprofit organizations, with funding available up to $275,000 over a two-year period. Interested parties should note that applications are accepted until December 16, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating individuals, and children. This initiative seeks to support translational and clinical research that develops novel therapeutic tools, enhances understanding of drug mechanisms, and improves medication safety and efficacy for these vulnerable populations. The program emphasizes interdisciplinary collaboration to address unmet therapeutic needs and promote better health outcomes in maternal and pediatric medicine. Applications will be accepted starting January 5, 2025, with a closing date of May 7, 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-110.html.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating persons, and children. This grant seeks to support innovative research that develops novel tools and technologies, enhances understanding of drug mechanisms, and improves therapeutic options for these populations, particularly those with disabilities. The initiative is part of the R21 Exploratory/Developmental Research Grants program, with a funding cap of $275,000 over a potential two-year period, and requires a Data Management and Sharing Plan as part of the application process. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov, with the application deadline set for May 7, 2026.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating persons, and children. This grant seeks to support translational and clinical research that develops novel tools and methodologies to enhance the understanding of drug action mechanisms and improve the safety and effectiveness of therapeutics for these populations. The initiative is crucial for addressing critical gaps in healthcare for vulnerable groups, with a focus on discovering safer medications and utilizing innovative approaches such as machine learning for precision dosing. Interested applicants can find more information and submit proposals by May 7, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for HIV Pediatric, Adolescent and Maternal Clinical Trials
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on high-priority HIV studies targeting infants, children, adolescents, young adults, and maternal populations. This initiative aims to establish an HIV clinical trials network dedicated to these demographics, fostering innovative and collaborative clinical trials to address significant research areas in HIV and related health issues. The estimated total program funding is $30 million, with two awards anticipated, and potential applicants are encouraged to begin forming collaborations and developing proposals ahead of the expected synopsis posting on November 21, 2025. For further inquiries, interested parties may contact Dr. Sonia Lee at Sonia.lee@nih.gov or by phone at 301-594-4783.
    Informatics, Coordination and Service Center for the Mutant Mouse Resource and Research Centers (U42 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the Informatics, Coordination and Service Center (ICSC) within the Mutant Mouse Resource and Research Centers (MMRRC) consortium, aimed at enhancing biomedical research through improved informatics services. The initiative seeks to support projects that develop and assist resources related to animal and biological materials, focusing on the integration of new approach methodologies (NAMs) alongside traditional animal-based research. This funding opportunity, utilizing the U42 activity code, is expected to provide a total of $878,000, with one award anticipated, and applications will be accepted starting in Summer 2025, following the NOFO publication in Spring 2025. For further inquiries, interested applicants can contact Dr. Oleg Mirochnitchenko at oleg.mirochnitchenko@nih.gov or by phone at 301-425-0479.
    Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality" (NOFO PAR-24-059). This initiative aims to support multidisciplinary research focused on addressing the high rates of maternal morbidity and mortality in the United States, particularly among racial and ethnic minorities, socioeconomically disadvantaged groups, and underserved rural populations. The program encourages innovative intervention studies that evaluate healthcare factors affecting maternal health, with the goal of reducing disparities and improving outcomes across the continuum of care from prenatal to postpartum. Eligible applicants include a range of organizations, and awards can last up to five years, with budgets tailored to project needs. Interested parties can find more information and apply by visiting the NIH grants website, with the application deadline set for January 7, 2027.
    Forecast to Renew the Notice of Funding Opportunity Announcement for the Multiple Chronic Disease Research Centers
    National Institutes of Health
    The National Institutes of Health (NIH) is set to renew the Notice of Funding Opportunity (NOFO) for the Multiple Chronic Disease Research Centers, aimed at enhancing research on the prevention, diagnosis, treatment, and management of multiple chronic diseases (MCDs). This initiative will support both existing and new regional comprehensive research centers that focus on innovative strategies and interventions to improve health outcomes, particularly among populations facing health disparities. With an estimated total program funding of $55 million and the expectation of awarding 11 grants, potential applicants are encouraged to begin forming collaborations and developing projects, as applications are not currently being solicited. For further inquiries, interested parties may contact Dr. Dolly Penn at dolly.penn@nih.gov or by phone at 301-496-8676, with key deadlines including an estimated synopsis post date of May 16, 2025, and a close date of July 25, 2025.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for collaborative, multi-site research focused on advancing the diagnosis, management, and treatment of rare diseases, with an emphasis on addressing unmet clinical trial readiness needs. The funding, estimated at $1 million, will support specialized centers through cooperative agreements, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare to develop meaningful collaborations, as the estimated award date is set for July 1, 2025.